Hepatitis C News and Research

Latest Hepatitis C News and Research

Study findings suggest potential targets for treating HCV

The hepatitis C virus (HCV) has a previously unrecognized tactic to outwit antiviral responses and sustain a long-term infection. It also turns out that some people are genetically equipped with a strong countermeasure to the virus' attempt to weaken the attack on it.

11 Feb 2014

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.

11 Feb 2014

TSRI scientists discover unusual protein that probably helps some bacteria evade immune response

A team led by scientists at The Scripps Research Institute (TSRI) has discovered an unusual bacterial protein that attaches to virtually any antibody and prevents it from binding to its target. Protein M, as it is called, probably helps some bacteria evade the immune response and establish long-term infections.

7 Feb 2014

Researchers design new vaccine for human-infecting respiratory syncytial virus

Vaccines are the safest, cheapest and most effective way to protect against infectious diseases. But to make a good one is still a challenge, and traditional approaches are now stretched to the limit while fatal diseases, like HIV and malaria, remain without vaccine.

6 Feb 2014

Alabama experts develop living document that includes new therapies for Hepatitis C virus

When treatment guidelines for a particular disease emerge, they are often published in a peer-reviewed medical journal, which can take up to three years. One University of Alabama at Birmingham infectious diseases expert recently helped develop new Hepatitis C virus (HCV) guidelines that can be updated and published as new data emerge and new therapies are approved.

5 Feb 2014

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

31 Jan 2014

Daclatasvir–sofosbuvir combo effective in chronic HCV infection

Research shows that the combination of daclatasvir and sofosbuvir leads to high rates of sustained virologic response in patients with chronic hepatitis C virus infection, including those who have not responded to previous therapy.

24 Jan 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

Morbidity following liver transplant is highest among obese patients with diabetes

Researchers from New Zealand report that morbidity following liver transplant is highest among obese patients with diabetes, but these risk factors do not influence post-transplant survival.

24 Jan 2014

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals, Inc. today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the DNA vaccines in a preclinical study.

23 Jan 2014

Research roundup: Nursing home transitions; the impact of raising Medicare premiums; workers' views of job-based insurance

Each week, KHN compiles a selection of recently released health policy studies and briefs.

20 Jan 2014

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Sovaldi (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C infection in adults, in combination with other antiviral agents (ribavirin and pegylated interferon alpha (peg-IFN)).

18 Jan 2014

Study: Pro-inflammatory molecules linked with early death in HIV patients who abuse alcohol

A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.

17 Jan 2014

Severe infection associated with increased risk for psychotic illness

Hospital admission for infections in childhood is associated with an increased risk for being diagnosed with nonaffective psychosis later in life, research indicates.

16 Jan 2014

Monitoring individuals with chronic HBV is cost-effective strategy for China

A novel study determined that monitoring inactive chronic hepatitis B (HBV) carriers is a cost-effective strategy for China. However, results published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that increasing treatment, monitoring and adherence to therapy are necessary to achieve significant health benefits at the population level.

16 Jan 2014

New drug combination proves effective in treatment of hepatitis C

Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.

16 Jan 2014

Hepatitis C infection varies widely among different Hispanic groups in the U.S.

The first study of hepatitis C infection among different Hispanic groups in the U.S. has found that infection with the virus varies widely, with Puerto Rican Hispanics much more likely than other groups to be infected. The study, led by researchers at Albert Einstein College of Medicine of Yeshiva University, highlights which Hispanic populations would benefit most from increased hepatitis C testing and treatment.

15 Jan 2014

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Pulmonary fibrosis is a condition where fibrotic or scarred tissue progressively develops in the lungs. In some cases the particular cause is known but in others it remains unknown and is given the term “idiopathic”.

14 Jan 2014

Viewpoints: Don't blame insurers for health system problems; Obama's 'management failure;' Texas abortion case heads to court

[The] problem with the Affordable Care Act isn't the insurance industry. In fact, the main benefits of nationalized health care can be achieved in systems with hundreds, even thousands, of for-profit insurers. ...

10 Jan 2014

AHF opens new Men's Wellness Center in Brooklyn in partnership with GMAD

AIDS Healthcare Foundation will open its newest Men's Wellness Center in Brooklyn on Wednesday in partnership with local nonprofit Gay Men of African Descent.

8 Jan 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

Study findings suggest potential targets for treating HCV

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

TSRI scientists discover unusual protein that probably helps some bacteria evade immune response

Researchers design new vaccine for human-infecting respiratory syncytial virus

Alabama experts develop living document that includes new therapies for Hepatitis C virus

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

Daclatasvir–sofosbuvir combo effective in chronic HCV infection

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Morbidity following liver transplant is highest among obese patients with diabetes

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Research roundup: Nursing home transitions; the impact of raising Medicare premiums; workers' views of job-based insurance

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Study: Pro-inflammatory molecules linked with early death in HIV patients who abuse alcohol

Severe infection associated with increased risk for psychotic illness

Monitoring individuals with chronic HBV is cost-effective strategy for China

New drug combination proves effective in treatment of hepatitis C

Hepatitis C infection varies widely among different Hispanic groups in the U.S.

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Viewpoints: Don't blame insurers for health system problems; Obama's 'management failure;' Texas abortion case heads to court

AHF opens new Men's Wellness Center in Brooklyn in partnership with GMAD

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Hepatitis C News and Research

Latest Hepatitis C News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in